newsfilter
← Latest News
Business Wire·

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Four abstracts accepted across melanoma, colorectal cancer, and translational research Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab